Metraipolis › archive › dc_1597298ec296
Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41753212
- DOI
- 10.3390/jcm15041525
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T19:36:25.510Z
- SHA-256 of the archived text
fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8- Stable URL of this page
https://metraipolis.com/documento/dc_1597298ec296
How to cite
Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212 — Europe PMC (en), https://europepmc.org/article/MED/41753212 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1597298ec296 (Metraipolis archive dc_1597298ec296, sha256 fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8)
BibTeX
@misc{dc1597298ec296,
title = {Dupilumab-Related Hypereosinophilia in Patients Treated for Type 2 Diseases: Evidence from a 24-Month Prospective Real-Life Study — Europe PMC PMID:41753212},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41753212},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1597298ec296; sha256 fbae2f463d93e0de1654746dd64c6543969d5f224de0f002555429a1adceeac8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41753212. Agents can read the archived copy with the MCP tool read_document.